The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors. With the recent approval by the U.S. Food and Drug Administration (FDA) of ...

Cabometyx is approved for treating well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older. The phase 3 CABINET trial showed improved progression-free ...

such as C 11-5HTP or Ga 68-DOTA octreotate, will improve staging and follow-up of therapy in patients with neuroendocrine tumors. Somatostatin analogs (e.g., octreotide, lanreotide) will continue ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors, as shown in the phase 3 CABINET trial. The trial demonstrated a median PFS ...

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. The small-molecule drug is now allowed for patients 12 years of age and ...

Getty A new study has found that the radiation from CT scans could eventually lead to over 100,000 future cancer diagnoses. On Monday, April 14, JAMA Internal Medicine — a monthly peer-reviewed ...

But in March 2024, the mom of two was rushed to the hospital with abdominal pain for suspected appendicitis. Scans discovered her cancer had spread to her ovaries and abdominal wall.